- Investing Ideas
- U.S. Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
U.S. Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
Results
10
Companies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.
10 companies
AbbVie
Market Cap: US$458.2b
A research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide.
ABBV
US$256.91
7D
1.4%
1Y
36.3%
Merck
Market Cap: US$323.7b
Operates as a healthcare company worldwide.
MRK
US$130.76
7D
5.1%
1Y
55.6%
Travere Therapeutics
Market Cap: US$5.3b
A biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States.
TVTX
US$56.68
7D
2.2%
1Y
268.1%
Sotera Health
Market Cap: US$4.9b
Provides sterilization solutions, lab testing, and advisory services for the healthcare industry in the United States, Canada, Europe, and internationally.
SHC
US$17.24
7D
-1.0%
1Y
40.3%
SIGA Technologies
Market Cap: US$223.1m
A commercial-stage pharmaceutical company, focuses on the health security market in the United States.
SIGA
US$3.10
7D
-10.9%
1Y
-57.0%
Mesa Laboratories
Market Cap: US$545.6m
Develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally.
MLAB
US$97.77
7D
1.1%
1Y
26.5%
Ligand Pharmaceuticals
Market Cap: US$6.0b
A biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide.
LGND
US$297.50
7D
1.2%
1Y
120.5%
Waters
Market Cap: US$36.8b
Provides analytical workflow solutions in Asia, the Americas, and Europe.
WAT
US$371.20
7D
3.8%
1Y
22.8%
BioLife Solutions
Market Cap: US$1.5b
Develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally.
BLFS
US$29.79
7D
2.4%
1Y
34.0%
Repligen
Market Cap: US$7.4b
A life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally.
RGEN
US$131.06
7D
-9.9%
1Y
9.5%